Epirubicin hydrochloride Manufacturer/High quality Epirubicin HCL High purity 99% Epirubicin hcl Supplier in china
Epirubicin hydrochloride Basic information |
Product Name: | Epirubicin hydrochloride |
Synonyms: | CS-1396;Epirubicin hydrochloride, ≥90% (HPLC);Epirubicin Hydrochloride - CAS 56390-09-1 - Calbiochem;epi-Doxorubicin HCl;Epirubicin HCl (4'-epidoxorubicin);ELLENCE; PHARMORUBICIN; EPIRUBICIN EBEWE;Epirubicin Ebewe;Epirubicin hydrochloride, >=99% |
CAS: | 56390-09-1 |
MF: | C27H30ClNO11 |
MW: | 579.9802 |
Epirubicin hydrochloride Chemical Properties |
Melting point | 185°C dec. |
alpha | D20 +274° (c = 0.01 in methanol) |
RTECS | QI9295750 |
Fp | 443.8℃ |
storage temp. | Desiccate at +4°C |
solubility | Soluble in DMSO to 100mM, or in ethanol to 10mM |
form | powder |
color |
red to deep red |
Epirubicin hydrochloride Usage And Synthesis |
Description | Epirubicin hydrochloride is an antitumor antibiotic which is epimeric with doxorubicin a t the 4’-position of the amino sugar moiety. It has shown utility in the treatment of mammary, gastric, colorectal, pulmonary and ovarian carcinomas, as well as malignant lymphoma and melanoma and soft tissue sarcoma. It is reported to be less sardiotoxic than doxorubicin. |
Chemical Properties | Orange-Red Crystalline Solid |
Originator | Erbamont (Italy) |
Uses | Used as an antineoplastic |
Brand name | Ellence(Pfizer);FARMORUBICIN. |
Biological Functions | This stereoisomer of doxorubicin has the 4′-hydroxy group of the daunosamine sugar oriented in the β-position . Epirubicin will be slowly reduced to the active C13 alcohol (epirubicinol), giving it a 30- to 38-hour half life, which is similar to that of doxorubicin. Unlike doxorubicinol, however, which was equally active with doxorubicin, epirubicinol has only one-tenth the activity of its parent drug and is not believed to contribute significantly to the therapeutic action of this agent. |
Biological Activity | Antibiotic antitumor agent. Inhibits the synthesis and function of DNA (IC 50 = 62.7 μ M in rat glioblastoma cell lines) and inhibits the relaxing property of topoisomerase II. |
Clinical Use | Epirubicin is indicated for use in breast cancer, and the starting dose is 100 to 120 mg/m2 (compared to a starting dose of 60–75 mg/m2 for doxorubicin). |
Side effects | The side effects and precautions are as outlined previously for doxorubicin, although there is a lower risk of serious myocardial toxicity or myelotoxicity. |
Metabolism | Cleavage of the epimerized sugar will occur before excretion, generating an aglycone that is indistinguishable from that generated by doxorubicin. Although excretion is primarily biliary, dosage reduction in severe renal impairment, as well as in hepatic dysfunction, is warranted. |
CAS NO:553-86-6
CAS NO:530-57-4
CAS NO:144292-32-0
CAS NO:154127-42-1
CAS NO:1290139-67-1
CAS NO:308831-94-9
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View